智通财经APP获悉，周二，医疗保险股盘前集体大跌，哈门那(HUM.US)股价重挫逾16%，联合健康 (UNH.US)大跌15%，西维斯健康(CVS.US)跌近10%。消息面上，美国政府提议明年将联邦医疗保险 (Medicare)私人计划的支付费率维持在当前水平，这一消息令投资者大失所望。 另外，联合健康公布的第四季度盈利略微超出预期，但2026年收入指引疲软。根据LSEG汇编的数据， 联合健康第四季度经调整后每股收益为 2.11 美元，高于分析师平均预期的 2.10 美元。Q4营收为 1132 亿美元，尽管同比增长约 12%，但仍比华尔街预期低5.2亿美元。该公司还预测，2026 年收入将出现下 滑，这将是三十多年来收入首次年度萎缩。 美国医疗保险和医疗补助服务中心(CMS)在公告中表示，预计2027年联邦医保优势计划(Medicare Advantage)的支付费率仅将上调0.09%，远低于分析师此前预期的高达6%的增幅。支付费率对联合健 康、西维斯健康和哈门那等大型保险商至关重要。支付费率提高能帮助保险公司覆盖医疗成本、提升老 年客户福利并增厚利润，而小幅上调则会直接压缩企业利润率。 ...

Market Overview - As of January 27, U.S. stock index futures showed mixed results with Dow futures down 0.48%, S&P 500 futures up 0.23%, and Nasdaq futures up 0.60% [1] - European indices also displayed varied performance, with Germany's DAX down 0.12%, UK's FTSE 100 up 0.36%, France's CAC40 up 0.37%, and the Euro Stoxx 50 up 0.29% [3] - WTI crude oil decreased by 0.23% to $60.49 per barrel, while Brent crude oil fell by 0.25% to $64.61 per barrel [3] Investment Insights - UBS forecasts the S&P 500 could reach 8,400 points by year-end, driven by opportunities in artificial intelligence, longevity technology, and energy [4] - Amundi highlights a shift from dollar assets to gold, predicting continued strength in gold prices due to rising U.S. fiscal deficits and uncertainty in monetary policy [6] - Silver prices have surged over 7%, but concerns about speculative trading and potential corrections have been raised [7] Company-Specific Developments - UnitedHealth reported Q4 revenue of $113.22 billion, slightly below expectations, and provided a 2026 revenue guidance of $439 billion, also below market forecasts [10] - Boeing exceeded revenue expectations with Q4 revenue of $23.9 billion [10] - UPS reported Q4 revenue of $24.5 billion, surpassing expectations, and raised its 2026 revenue guidance to approximately $89.7 billion [10] - General Motors' Q4 revenue fell 5% to $45.3 billion, but it announced a $6 billion stock buyback plan and provided a positive 2026 earnings outlook [11] - Micron Technology plans to increase investment in storage chip manufacturing in Singapore to address global shortages [13] - Nike is cutting 775 jobs in its U.S. distribution centers as part of a strategy to streamline operations and enhance automation [14]

Market Analysis by covering: Humana Inc. Read 's Market Analysis on Investing.com ...

UnitedHealth, Humana, CVS Dive On Flat 2027 Medicare Advantage Rates | Investor's Business DailyMUST- VIEW FOR INVESTORS: [See The Best Online Brokers For 2026]---UnitedHealth (UNH), Humana (HUM), CVS Health (CVS) and other S&P 500 health insurance stocks were pummeled overnight after the Trump administration announced a preliminary plan to keep Medicare reimbursement rates nearly flat in 2027, far below expectations. The diminished Medicare outlook for 2027 overshadowed Tuesday morning's mixed fourth-quart ...

U.S. stock futures are presenting a mixed picture this Tuesday, January 27, 2026, as investors navigate a busy week dominated by corporate earnings reports, a crucial Federal Reserve policy meeting, and fresh geopolitical developments. While technology-focused futures show upward momentum, broader market indicators suggest a more cautious approach in premarket trading.Premarket Activity and Index FuturesAs of early Tuesday, premarket trading indicates a divergence among the major U.S. indexes. Nasdaq 100 fu ...

The Trump administration proposed keeping Medicare rates roughly flat this year. ...

China's Anta Sports paid a big premium but doesn't appear likely to launch bid for all of Puma. ...

Company Overview - CVS Health Corporation has a market cap of $105.4 billion and provides integrated health solutions through its Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments, offering health insurance, pharmacy benefit management, and retail pharmacy services nationwide [1] Stock Performance - CVS stock has significantly outperformed the broader market over the past 52 weeks, surging 53.8% compared to the S&P 500 Index's gain of 13.9% [2] - Year-to-date, CVS stock has risen 5.7%, while the S&P 500 Index has only gained 1.5% [2] - CVS shares have also outpaced the State Street Health Care Select Sector SPDR ETF's return of 9.6% over the past 52 weeks [3] Recent Financial Results - On October 29, CVS reported a Q3 2025 loss of $3.13 per share, primarily due to a $5.7 billion goodwill impairment charge related to its Health Care Delivery unit, resulting in a $3.2 billion operating loss compared to a profit the previous year [4] - The company has sharply cut its full-year 2025 EPS guidance to a loss of $(0.34) - $(0.24) from prior expectations of $3.84 - $3.94 [4] Future Earnings Expectations - For the fiscal year ending December 2025, analysts expect CVS' adjusted EPS to grow 22.7% year-over-year to $6.65, with a promising earnings surprise history [5] - Among 24 analysts covering the stock, the consensus rating is a "Strong Buy," based on 19 "Strong Buy" ratings, two "Moderate Buys," and three "Holds" [5] Analyst Ratings and Price Targets - The current analyst configuration is slightly less bullish than three months ago, with 20 "Strong Buy" ratings [6] - Bernstein raised its price target on CVS Health to $91 while maintaining a "Market Perform" rating, with a mean price target of $94.74, suggesting a nearly 13% premium to CVS' current price [6] - The highest price target of $105 indicates a potential upside of 25.2% [6]

Core Viewpoint - The proposed maintenance of the Medicare Advantage payment rates at current levels for next year has disappointed investors, leading to significant stock declines for major insurance companies [1]. Group 1: Payment Rate Impact - The Centers for Medicare & Medicaid Services (CMS) announced that the payment rate for Medicare Advantage plans is expected to increase by only 0.09% in 2027, far below analysts' expectations of a 6% increase [1][2]. - The total payment increase for Medicare Advantage plans in 2027 is projected to be just $700 million, which is minimal compared to the typical payment growth in the tens of billions [2]. - Payment rates are crucial for large insurers like UnitedHealth, CVS Health, and Humana, as the Medicare Advantage program has been a significant growth driver for the insurance industry over the past decade [1][3]. Group 2: Industry Challenges - The profitability of Medicare Advantage plans has been declining due to rising medical costs and insufficient government funding, leading to pressure on insurers [1][3]. - The insurance industry has expressed concerns that the government's payment levels have not kept pace with rising costs, impacting their profit margins [3]. - Analysts had previously predicted a payment increase of 5% to 6% for 2027, and a lower increase could significantly pressure insurance company stock prices [3].

Group 1 - The U.S. government proposed to maintain the payment rates for Medicare Advantage plans at current levels for next year, disappointing investors and causing significant stock declines for major insurance companies [1][2] - Major insurers such as UnitedHealth, CVS Health, and Humana experienced stock drops of 9.3%, 10%, and over 15% respectively following the announcement [1] - The Centers for Medicare & Medicaid Services (CMS) indicated that the payment rate increase for Medicare Advantage plans is expected to be only 0.09% by 2027, far below analysts' expectations of a 6% increase [1][2] Group 2 - The proposed payment rates imply minimal growth for Medicare Advantage insurers, who are already facing profit pressures due to rising medical costs and government funding shortfalls [1][2] - The total payment increase for Medicare Advantage plans in 2027 is projected to be only $700 million, a negligible amount compared to the typical multi-billion dollar growth in the industry [2] - CMS is working on additional policies aimed at improving payment accuracy, ensuring beneficiary choice, and providing reasonably priced insurance coverage for Medicare beneficiaries [2] Group 3 - The Medicare Payment Advisory Commission estimates that by 2025, the government costs for covering individuals through Medicare Advantage plans will increase by 20%, approximately $84 billion [3] - Insurance companies argue that the government payment levels have not kept pace with rising costs, leading to operational challenges in the Medicare Advantage business [3] - Analysts from TD Cowen previously predicted a payment rate increase of 5% to 6% for 2027, warning that a rate increase below 4% could significantly pressure insurance company stock prices [3]